A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease

@article{Choi2015AP2,
  title={A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease},
  author={J. Choi and B. Lee and J. M. Ko and Y. B. Sohn and Jin-Sung Lee and G. Kim and S. Heo and June-Young Park and Y. Kim and Ja-Hye Kim and Han-Wook Yoo},
  journal={Journal of Korean Medical Science},
  year={2015},
  volume={30},
  pages={378 - 384}
}
  • J. Choi, B. Lee, +8 authors Han-Wook Yoo
  • Published 2015
  • Medicine
  • Journal of Korean Medical Science
    • Gaucher disease is a lysosomal storage disease for which enzyme replacement therapy has proven to be effective. A switch-over clinical trial was performed to evaluate the efficacy and safety of Abcertin® (ISU Abxis, Seoul, Korea) in subjects with type 1 Gaucher disease who were previously treated with imiglucerase. Five Korean patients with type 1 Gaucher disease were enrolled. Previous doses of imiglucerase ranged from 30 to 55 U/kg every other week. The same dose of Abcertin® was administered… CONTINUE READING
    View on PubMed
    doi.org
    8 Citations
    Background Citations
    2
    Methods Citations
    1

    Supplemental Clinical Trials

    Observational Clinical Trial
    A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
    The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease previously treated with Imiglucerase.  
    ConditionsGaucher Disease
    ISU Abxis Co., Ltd.
    May 2011 - February 2012
    Explore Further
    Discover more papers related to the topics discussed in this paper

    Figures, Tables, and Topics from this paper

    Figures and Tables

    Explore Further: Topics Discussed in This Paper

    8 Citations
    Citation Type

    Citation Type

    A multicenter, open-label, phase III study of Abcertin in Gaucher disease
    • 3
    How we manage Gaucher Disease in the era of choices
    • 20
    Insight into Biosimilars: Short Description, Analytical Assessment and Market
    • PDF
    Substrate reduction therapy as a new treatment option for patients with Gaucher disease type 1: A review of literatures
    • PDF
    The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
    La maladie de Gaucher : quand y penser ?
    • 3
    Recent advances and future challenges in Gaucher disease.
    • 6
    Substrate reduction therapy in three patients with Gaucher disease

    References

    SHOWING 1-10 OF 27 REFERENCES
    Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study
    • 50
    Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
    • 106
    Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model
    • 37
    • PDF
    Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
    • 80
    • PDF
    A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease.
    • 52
    The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    • 106
    The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    • 85
    • PDF
    Replacement therapy with imiglucerase for type 1 Gaucher's disease
    • 101
    Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    • 1,081
    A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease
    • 52
    • PDF